Oak Brook, Illinois, United States The venture was found in North America in United States. The leading representative office of defined VC is situated in the Oak Brook.
The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Huizenga Capital Management, startups are often financed by Dolby Family Ventures, Takeda Ventures, Pfizer. The meaningful sponsors for the fund in investment in the same round are Vulcan Capital, Verily, Takeda Ventures. In the next rounds fund is usually obtained by OCA Ventures.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Impossible Objects, Eved, Cortexyme. The fund has exact preference in a number of founders of portfolio startups. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Handmade, Retail.
Speaking about the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. The top amount of exits for fund were in 2019. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in less than 2 deals every year. The high activity for fund was in 2015. Comparing to the other companies, this Huizenga Capital Management performs on 4 percentage points more the average number of lead investments.
The overall number of key employees were 1.
Related Funds
Funds with similar focus
| Fund Name | Location |
| 8i Ventures | India, Maharashtra, Mumbai |
| Aventrock Ventures | Alberta, Calgary, Canada |
| Charlesbank Capital Partners | Boston, Massachusetts, United States |
| Cycle Venture Partners | - |
| Dajin Heavy Industries | China, Fuxin, Liaoning |
| Energy Innovation Capital | California, San Francisco, United States |
| Itera Capital | Distrito Federal, Mexico, Mexico City |
| MDC Ventures | New York, New York, United States |
| Novastar Ventures | Kenya, Nairobi, Nairobi Area |
| Noventi Ventures | - |
| Petercam | Belgium, Brussels, Brussels Hoofdstedelijk Gewest |
| PFA Pension | - |
| Rabo Frontier Ventures | Netherlands, Utrecht, Utrecht |
| RS Investments | California, San Francisco, United States |
| Salem Partners | California, Los Angeles, United States |
| Shanghai Xinfan Asset Management | China, Shanghai |
| Tuling Capital | - |
| Zhiyou Fangcun | China, Guangdong, Shenzhen |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
HiberCell | $67M | 19 May 2021 | New York, New York, United States | ||
Cortexyme | $76M | 31 May 2018 | South San Francisco, California, United States | ||
Impossible Objects | $6M | 10 Oct 2017 | Illinois, United States | ||
Eved | $14M | 16 Dec 2015 | Chicago, Illinois, United States |
– HiberCell, a NYC-based biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, completed a Series B financing round for gross proceeds of $67.4m.
– The company closed on a $30m debt facility with Hercules Capital, Inc. (NYSE: HTGC).
– The Series B round included new investors Huizenga Capital Management, Monashee Investment Management, funds managed by Tekla Capital Management LLC, Hercules Capital, Mount Sinai Innovation Partners and other undisclosed investors.
– Returning investors, including ARCH Venture Partners, Magnetic Ventures, Bristol Myers Squibb, Trinitas Capital, and others from the Series A syndicate also participated in the round.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
HiberCell | $67M | 19 May 2021 | New York, New York, United States | ||
Cortexyme | $76M | 31 May 2018 | South San Francisco, California, United States | ||
Impossible Objects | $6M | 10 Oct 2017 | Illinois, United States | ||
Eved | $14M | 16 Dec 2015 | Chicago, Illinois, United States |
